Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
Paulus F KirchhofLadislav PecenAmeet BakhaiCarlo de AsmundisJoris R de GrootJean Claude DeharoPeter KellyPierre LevyEsteban Lopez-de-SaPedro MonteiroJan SteffelJohannes WaltenbergerThomas W WeissPetra LaeisMarius Constantin ManuJosé SouzaRaffaele De CaterinaPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
Patients treated with edoxaban in ETNA-AF-Europe reported low two-year event rates in unselected AF patients. Prior stroke, reduced kidney function, and HF identify patients at high risk of stroke, bleeding and all-cause/cardiovascular death, respectively.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- direct oral anticoagulants
- end stage renal disease
- heart failure
- percutaneous coronary intervention
- venous thromboembolism
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- clinical practice
- quality improvement
- patient reported outcomes
- left ventricular
- brain injury